- Home
- ELEV vs IXHL Comparison
ELEV vs IXHL Comparison
Compare ELEV & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- IXHL
- Stock Information
- Founded
- ELEV 2019
- IXHL 2001
- Country
- ELEV United States
- IXHL Australia
- Employees
- ELEV N/A
- IXHL N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- IXHL
- Sector
- ELEV Health Care
- IXHL
- Exchange
- ELEV Nasdaq
- IXHL Nasdaq
- Market Cap
- ELEV 37.6M
- IXHL 39.2M
- IPO Year
- ELEV 2021
- IXHL N/A
- Fundamental
- Price
- ELEV $0.58
- IXHL $1.71
- Analyst Decision
- ELEV Strong Buy
- IXHL
- Analyst Count
- ELEV 5
- IXHL 0
- Target Price
- ELEV $7.20
- IXHL N/A
- AVG Volume (30 Days)
- ELEV 860.8K
- IXHL 18.1K
- Earning Date
- ELEV 11-06-2024
- IXHL 11-14-2024
- Dividend Yield
- ELEV N/A
- IXHL N/A
- EPS Growth
- ELEV N/A
- IXHL N/A
- EPS
- ELEV N/A
- IXHL N/A
- Revenue
- ELEV N/A
- IXHL $86,000.00
- Revenue This Year
- ELEV N/A
- IXHL $3,817.06
- Revenue Next Year
- ELEV N/A
- IXHL $66.67
- P/E Ratio
- ELEV N/A
- IXHL N/A
- Revenue Growth
- ELEV N/A
- IXHL N/A
- 52 Week Low
- ELEV $0.44
- IXHL $1.50
- 52 Week High
- ELEV $5.83
- IXHL $8.47
- Technical
- Relative Strength Index (RSI)
- ELEV 43.94
- IXHL 40.83
- Support Level
- ELEV $0.60
- IXHL $1.60
- Resistance Level
- ELEV $0.70
- IXHL $2.08
- Average True Range (ATR)
- ELEV 0.08
- IXHL 0.11
- MACD
- ELEV -0.01
- IXHL 0.02
- Stochastic Oscillator
- ELEV 7.67
- IXHL 22.92
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.